Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery (ERAS) Protocol in Subjects Undergoing Bowel Resection
Latest Information Update: 09 Jan 2026
At a glance
- Drugs TU 100 (Primary)
- Indications Postoperative ileus
- Focus Proof of concept; Therapeutic Use
- Sponsors Tsumura
Most Recent Events
- 01 Jan 2026 Primary endpoint has been met (Time to gastrointestinal recovery (GIR)), according to Results published in the Diseases of the Colon and Rectum
- 01 Jan 2026 Results published in the Diseases of the Colon and Rectum
- 25 Jul 2024 Status changed from active, no longer recruiting to completed.